Knight Therapeutics Inc.
Knight Therapeutics Inc. (GUD.TO) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
gud.to · stock forecast · 1 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 1 Wall Street analysts in the past 3 months
Buy
1 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $9.14
Short-Term Price Prediction
BullAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $9.28 | ↑ 1.55% |
1-day model range: $9.23–$9.33. Peak: $9.33 (+1.55%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $11 | +22.0% |
| 2028 | $13 | +36.8% |
| 2029 | $13 | +46.0% |
| 2030 | $14 | +51.3% |
| 2031 | — | +54.4% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · GUD.TO · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-03-06 | Raymond James | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Knight Therapeutics Inc. (GUD.TO) stock. Of the recent 1 rating actions, 0 were upgrades and 0 were downgrades. 1 analysts currently cover GUD.TO.
Analyst Recommendation Trends
GUD.TO analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$520M
↓ 5.0% YoY
Revenue Next Year
$528M
↑ 1.4% YoY
EPS This Year
$0.18
EPS Next Year
$0.21
↑ 14.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast GUD.TO EPS of $0.18 for the current fiscal year, based on estimates from 3 analysts. The GUD.TO revenue forecast is $520M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The GUD.TO stock forecast is supported by two independent data sources: analyst consensus ratings from 1 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus GUD.TO price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The GUD.TO short-term stock prediction for tomorrow is $9.28 (+1.55%). The GUD.TO stock price prediction for 2027 estimates an average of $11. The GUD.TO stock prediction for 2030 projects a range of $13–$15.
Knight Therapeutics Inc. trades on TSX under the ticker GUD.TO. The GUD.TO stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
GUD.TO forecast · 8 questionsAccording to 1 Wall Street analysts, the average 12-month GUD.TO price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $9.14.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.